Zeo ScientifiXZEOX 50 Current Ratio is 1.05 as of Apr. 2026, which is 453% above its 10-year median of 0.19. GuruFocus rates ZEOX with a GF Score™ of 50/100 and a GF Value™ of $2.67 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,413 Biotechnology companies, Zeo ScientifiX ranks worse than 83.3% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Zeo ScientifiX's current ratio for the quarter that ended in Apr. 2026 was 1.05.
Zeo ScientifiX has a current ratio of 1.05. It generally indicates good short-term financial strength.
The historical rank and industry rank for Zeo ScientifiX's Current Ratio or its related term are showing as below:
ZEOX'
s Current Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.19 Max: 1.07
Current: 1.05
During the past 13 years, Zeo ScientifiX's highest Current Ratio was 1.07. The lowest was 0.02. And the median was 0.19.
ZEOX's Current Ratio is ranked worse than 83.3% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs ZEOX: 1.05
Zeo ScientifiX (OTCPK:ZEOX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Zeo ScientifiX Current Ratio Related Terms
Zeo ScientifiX Current Ratio Historical Data
* Premium members only.
The historical data trend for Zeo ScientifiX's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZEOX vs LNAI, GDTC, HOOK: Current Ratio Comparison
For the Biotechnology subindustry, Zeo ScientifiX's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Current Ratio distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX (ZEOX) has a Current Ratio of 1.05 as of Apr. 2026. This is 453% above median its historical median of 0.19. Over the past decade, Zeo ScientifiX's Current Ratio has ranged from 0.02 to 1.07. According to the industry distribution chart, Zeo ScientifiX ranks #1177 out of 1413 companies in the Biotechnology industry, placing it in the top 83.3%.
Is Zeo ScientifiX's Current Ratio too high?
Zeo ScientifiX's current Current Ratio of 1.05 is 453% above median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 1.07. The Biotechnology industry median Current Ratio is 3.89. Zeo ScientifiX's value of 1.05 is 73% below this industry median. Based on the distribution chart, Zeo ScientifiX ranks #1177 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zeo ScientifiX has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's Current Ratio compare to LNAI and GDTC?
According to the Biotechnology industry distribution chart, Zeo ScientifiX ranks #1177 out of 1413 companies for Current Ratio. This places Zeo ScientifiX in the lower half of its industry. The industry median Current Ratio is 3.89. Zeo ScientifiX's value of 1.05 is 73% below this benchmark. Historically, Zeo ScientifiX's own Current Ratio has ranged from 0.02 to 1.07 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 3.89, Zeo ScientifiX has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeo ScientifiX's current Current Ratio of 1.05 is 73% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeo ScientifiX's current Current Ratio is 1.05, which is 453% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.67, compared to a current price of $1.75 — trading 34.5% below its estimated fair value. The current Current Ratio is 1.05, which is 453% above median its 10-year median of 0.19 and 73% below the Biotechnology industry median of 3.89. Zeo ScientifiX's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current Current Ratio is 1.05 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeo ScientifiX (ZEOX) Overvalued in 2026?
Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued.
The current stock price of $1.75 is trading 34.5% below its estimated GF Value™ of $2.67.
GuruFocus considers Zeo ScientifiX to be Possible Value Trap.
Key valuation signals for ZEOX:
Current Ratio: 1.05 (453% above median its 10-year median of 0.19)
GF Value™: $2.67 vs. price of $1.75 (34.5% below fair value)
Industry Position: 73% below the Biotechnology median (#1177 of 1413)
No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
50GF Score
Get the complete analysis for ZEOX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZEOX has been successfully added to your 
